Zachary Roberts - Jan 24, 2025 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
EVP of R&D
Signature
/s/Earl Douglas, Attorney-in-Fact
Stock symbol
ALLO
Transactions as of
Jan 24, 2025
Transactions value $
$0
Form type
4
Date filed
1/28/2025, 08:13 PM
Previous filing
Jan 23, 2025
Next filing
Feb 5, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +174K +35.63% $0.00 662K Jan 24, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to buy) Award $0 +615K $0.00 615K Jan 24, 2025 Common Stock 615K $1.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.